Shield Therapeutics (STX) Competitors GBX 2.95 +0.28 (+10.28%) (As of 11:45 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines STX vs. ELX, APC, DGI, STK, IDEA, DNL, EAH, CHLL, PXS, and MXCShould you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), Apc Technology Group (APC), DG Innovate (DGI), StreaksAI (STK), Ideagen (IDEA), Diurnal Group (DNL), ECO Animal Health Group (EAH), Chill Brands Group (CHLL), Provexis (PXS), and Argent BioPharma (MXC). Shield Therapeutics vs. El Oro Apc Technology Group DG Innovate StreaksAI Ideagen Diurnal Group ECO Animal Health Group Chill Brands Group Provexis Argent BioPharma Shield Therapeutics (LON:STX) and El Oro (LON:ELX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment. Is STX or ELX more profitable? El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -168.42%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Shield Therapeutics-168.42% -261.67% -47.85% El Oro N/A N/A N/A Does the MarketBeat Community believe in STX or ELX? Shield Therapeutics received 162 more outperform votes than El Oro when rated by MarketBeat users. Likewise, 75.17% of users gave Shield Therapeutics an outperform vote while only 59.55% of users gave El Oro an outperform vote. CompanyUnderperformOutperformShield TherapeuticsOutperform Votes21575.17% Underperform Votes7124.83% El OroOutperform Votes5359.55% Underperform Votes3640.45% Do insiders & institutionals have more ownership in STX or ELX? 11.9% of Shield Therapeutics shares are held by institutional investors. 62.2% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, STX or ELX? El Oro has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShield Therapeutics£21.47M1.07-£36.17M-£0.04-73.75El Oro-£7.25M-5.66N/A-£2.50-26.00 Does the media refer more to STX or ELX? In the previous week, Shield Therapeutics had 2 more articles in the media than El Oro. MarketBeat recorded 2 mentions for Shield Therapeutics and 0 mentions for El Oro. Shield Therapeutics' average media sentiment score of 0.00 equaled El Oro'saverage media sentiment score. Company Overall Sentiment Shield Therapeutics Neutral El Oro Neutral SummaryShield Therapeutics beats El Oro on 8 of the 12 factors compared between the two stocks. Ad Darwin2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STX vs. The Competition Export to ExcelMetricShield TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£23.07M£1.15B£5.10B£1.40BDividend YieldN/A3.13%5.04%11.79%P/E Ratio-73.75109.9795.121,555.80Price / Sales1.071,897.431,217.30210,506.32Price / Cash6.3610.2639.4933.06Price / BookN/A3.056.972.81Net Income-£36.17M£155.48M£118.73M£153.14M7 Day Performance12.38%-1.16%-1.22%-0.48%1 Month Performance-34.73%-3.87%-3.07%7.21%1 Year Performance-51.91%90.08%32.52%93.59% Shield Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STXShield TherapeuticsN/AGBX 2.95+10.3%N/A-56.1%£23.07M£21.47M-73.7540,000News CoverageGap UpHigh Trading VolumeELXEl OroN/AGBX 65flatN/A+0.0%£41.06M£-7,248,605.00-26.001,122APCApc Technology GroupN/AGBX 9.88flatN/A+0.0%£18.03M£19.20M19.75164,000DGIDG InnovateN/AGBX 0.08-2.6%N/A+100.0%£9.04M£24,500.00-1.25790High Trading VolumeSTKStreaksAIN/AGBX 0.18-7.9%N/A-77.4%£663,000.00N/A-32.503Positive NewsGap DownHigh Trading VolumeIDEAIdeagenN/AGBX 349-0.3%N/A+0.0%£1.03B£75.28M17,450.009DNLDiurnal GroupN/AGBX 27.30flatN/A+0.0%£46.33M£4.68M-3.2133EAHECO Animal Health GroupN/AGBX 63.77-3.4%N/A-41.3%£43.20M£89.42M3,300.00234Gap DownCHLLChill Brands GroupN/AGBX 2.15flatN/AN/A£10.89M£624,187.00-215.007PXSProvexisN/AGBX 0.46-12.4%N/A-8.2%£10.37M£426,168.0043.754Gap DownMXCArgent BioPharmaN/AGBX 22+4.8%N/A-43.6%£9.65M£1.32M-13.255Gap Up Related Companies and Tools Related Companies ELX Competitors APC Competitors DGI Competitors STK Competitors IDEA Competitors DNL Competitors EAH Competitors CHLL Competitors PXS Competitors MXC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:STX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
